We combine large firm expertise with small firm attention. Our clients can expect the best results and the most personal experience.
LivePerson is facing a class action lawsuit alleging that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) LivePerson failed to address any material weaknesses with internal controls; (2) LivePerson’s third quarter financial statements, ended in September 30, 2022 failed to disclose its subsidiary, WildHealth’s, suspension of Medicare reimbursement; (3) as a result, LivePerson’s fourth quarter 2022 revenue would be affected; and (4) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you incurred a loss on LPSN securities purchased between May 10, 2022 and March 16, 2023, this lawsuit is on your behalf. The lawsuit was filed in the United States District Court for the Eastern District of New York, and our firm is reaching out to investors to discuss their legal rights.
If you wish to act as a representative of the shareholders harmed by this misconduct, you may ask the court to appoint you as lead plaintiff. A lead plaintiff directs the litigation and participates in important decisions, including whether to accept a settlement for the class in the action.
You only have until June 23, 2023 to apply to be lead plaintiff. The court will then evaluate the applicants and choose a lead plaintiff. You are not required to act as a lead plaintiff in order to participate in any recovery.
Enter the following information for this class action case- the deadline is approaching.
See If you Qualify for Monetary RewardLoss Submission Form